biostudies-literatureFigarella-Branger DInstitut National du Cancer755-766https://www.ebi.ac.uk/biostudies/studies/S-EPMC11889709biostudies-literatureUnknown27(3)<h4>Background</h4>In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).<h4>Methods</h4>494 patients from the POLA cohort, with a median follow-up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement (CE) in group 1 on overall survival (OS) or progression-free survival (PFS), survival curves were obtained (Kaplan-Meier method) and compared (log-rank test). The prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.<h4>Results</h4>Survival analysis demonstrated that the pNeuro-oncologyReappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.PMC11889709INCa_16828Appay RDehais CAndraud MDhermain FMokhtari KSeyve APOLA networkGuillamo JSNoel GCruel TAdam CGuillain NVandenbos-Burel FLhermitte BCohen-Moyal EMarguet FForest FRichard PYounan NGaultier CDesenclos CChiforeanu DRigau VRousseau AZemmoura IGhiringhelli FCampone MBlechet CDiebold MDColin CKhallil TLoussouarn DBernier MParker FAbad MFaillot TMeyronet DAdle-Biassette HLabrousse FBourg VCarpiuc IGauchotte GColin PRicard DRoger PMilin SLopez SWager MKhettab MTouat MMotso-Fotso MJHamdan NDjelad ACazals-Hatem DCarpentier AVauleon EIdbaih ACarpentier CDucray FBielle FTaillandier LUro-Coste EGueye EMSeizeur RChinot OMenei PAubriot-Lorton HLanglois OFigarella-Branger DBronnimann CTabouret ETortel MCMaurage CAChotard GGodfraind CQuintin-Roue IJoubert CBauchet LRousselot-Denis CfalseReappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.<h4>Background</h4>In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).<h4>Methods</h4>494 patients from the POLA cohort, with a median follow-up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement (CE) in group 1 on overall survival (OS) or progression-free survival (PFS), survival curves were obtained (Kaplan-Meier method) and compared (log-rank test). The prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.<h4>Results</h4>Survival analysis demonstrated that the p2025-01-01T00:00:00Z2025 Mar2026-06-04T13:34:52.868Z2026-05-09T03:12:23.274ZS-EPMC118897093943255910.1093/neuonc/noae221